Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

Clinical Microbiology and Infection

Volumn 18, Issue 7, 2012, Pages 680-687

  Ruhnke, M ^a   Paiva, J A ^b   Meersseman, W ^c   Pachl, J ^d   Grigoras, I ^e   Sganga, G ^f   Menichetti, F ^g   Montravers, P ^h   Auzinger, G ⁱ   Dimopoulos, G ^j   Borges Sa M ^k   Miller, P J ^l   Marcek T ^m   Kantecki, M ^m  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CHARLES UNIVERSITY   (Czech Republic)

^e GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h BICHAT HOSPITAL   (France)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

^j NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^k HOSPITAL SON LLÀTZER   (Spain)

^l PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^m PFIZER INC   (United States)

more..

Author keywords

Candida; Echinocandins; Efficacy; Global response; Intensive care unit; Safety

Indexed keywords

ANIDULAFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ABDOMINAL SURGERY; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BRONCHOSPASM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CONVULSION; CRITICALLY ILL PATIENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EXPLORATORY RESEARCH; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; INCIDENCE; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SOLID TUMOR; SURVIVAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 84862626460     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03784.x     Document Type: Article

References (31)

1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39: 665-670.
2. Vazquez JA. Invasive fungal infections in the intensive care unit. Semin Respir Crit Care Med 2010; 31: 79-86.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
4. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-1618.
5. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob Agents Chemother 2011; 55: 532-538.
6. Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54: 279-310.
7. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011; 46: 709-718.
8. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment. Intensive Care Med 2009; 35: 206-214.
9. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
10. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-5427.
11. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-156.
12. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009; 47: 3170-3177.
13. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
14. Kett DH, Shorr AF, Reboli AC et al . Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasi. Crit care 2011; 15: R253.
15. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13: R159.
16. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007; 22: 237-244.
17. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candidacolonization. Crit Care Med 2006; 34: 730-737.
18. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228.
19. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
20. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893.
21. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
22. Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60: 619-624.
23. Lewis JS, Graybill JR. Fungicidal versus Fungistatic: what's in a word? Expert Opin Pharmacother 2008; 9: 927-935.
24. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461-470.
25. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009; 53: 1149-1156.
26. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-2506.
27. Mayr A, Aigner M, Lass-Florl C. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect 2011; 17 (suppl 1): 1-12.
28. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
29. Cisterna R, Ezpeleta G, Telleria O. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol 2010; 48: 4200-4206.
30. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954-e966.
31. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.